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Abstract
Elucidating the relationships between antimicrobial resistance and virulence is key to under-
standing the evolution and population dynamics of resistant pathogens. Here, we show that
the susceptibility of the gram-positive bacterium Listeria monocytogenes to the antibiotic
fosfomycin is a complex trait involving interactions between resistance and virulence genes
and the environment. We found that a FosX enzyme encoded in the listerial core genome
confers intrinsic fosfomycin resistance to both pathogenic and non-pathogenic Listeria spp.
However, in the genomic context of the pathogenic L. monocytogenes, FosX-mediated
resistance is epistatically suppressed by two members of the PrfA virulence regulon, hpt
and prfA, which upon activation by host signals induce increased fosfomycin influx into the
bacterial cell. Consequently, in infection conditions, most L. monocytogenes isolates
become susceptible to fosfomycin despite possessing a gene that confers high-level resis-
tance to the drug. Our study establishes the molecular basis of an epistatic interaction
between virulence and resistance genes controlling bacterial susceptibility to an antibiotic.
The reported findings provide the rationale for the introduction of fosfomycin in the treatment
of Listeria infections even though these bacteria are intrinsically resistant to the antibiotic in
vitro.
Author summary
Epistasis, or interactions between genes, is the phenomenon where the phenotypic effect
of a locus is altered or masked by other loci in a given genomic context. Working with Lis-
teria bacteria, we show that the effect of an intrinsic resistance determinant that protects
these organisms against fosfomycin, a natural, microbial-derived antibiotic, is epistatically
cancelled by virulence determinants present in the pathogenic species, L. monocytogenes.
Since these virulence determinants are specifically activated within the host, the epistatic
effect only manifests during infection, not when the bacteria are living saprophytically.
Our study dissects the underlying mechanism, substantiating at the molecular level that
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virulence and resistance can be closely intertwined via gene-gene epistatic phenomena,
with strong effects on the antimicrobial susceptibility phenotype. The findings are signifi-
cant because any functional interaction between resistance and virulence may inextricably
link the evolution of these two key pathogen traits. Understanding in detail these interac-
tions is essential for predicting the evolutionary dynamics of resistance among pathogenic
microbes or the impact of antimicrobial policies on drug-resistant virulent strains. In
addition to their fundamental interest, our study provides the science-based evidence
needed for the use of fosfomycin to treat listeriosis, a severe foodborne infectious disease,
despite the causative bacteria showing strong resistance to the antibiotic.
Introduction
The facultative intracellular pathogen Listeria monocytogenes is the causative agent of list-
eriosis, a foodborne infection characterized by severe clinical manifestations including
meningoencephalitis, bacteremia, miscarriage and neonatal sepsis or meningitis [1–3]. The
pathogenesis of listeriosis relies on a group of virulence genes that are co-ordinately regulated
by the PrfA transcriptional activator [4]. PrfA-regulated genes are selectively induced within
host cells through a mechanism involving cofactor-mediated allosteric switching of PrfA
between weakly active (“Off”) and strongly active (“On”) states [5, 6]. PrfA regulation is both
essential for the activation of the listerial virulence program within the host and for preventing
the costly production of unneeded virulence factors when L. monocytogenes is living as an envi-
ronmental saprotroph [7, 8]. Listeriosis is the foodborne infection with the highest mortality
in the Western hemisphere despite hospital-based therapy (20–50%) [2]. This is partly attribut-
able to the intracellular lifestyle of L. monocytogenes and the location of lesions, e.g. the brain,
which render these bacteria relatively inaccessible to drugs thereby limiting the therapeutic
choices [9, 10]. Cell-permeant antimicrobials able to penetrate the blood-brain barrier (BBB)
and other listerial infection sites at bactericidal concentrations may therefore significantly aid
in the treatment of listeriosis.
Previous work from our laboratory identified fosfomycin (disodium salt for parenteral use)
[11–13] as one such potentially useful anti-listerial drugs. Fosfomycin [(1R,2S)-epoxypropyl-
phosphonic acid] is a low-molecular-weight bactericidal molecule discovered in 1969 in Strep-
tomyces fradiae [14] that inhibits peptidoglycan biosynthesis through covalent inactivation of
UDP-N-acetylglucosamine-3-enolpyruvyl transferase (MurA) [11]. Although known to be
resistant to fosfomycin by standard in vitro testing [9, 15, 16], we found that L. monocytogenes
was actually susceptible to this antibiotic in infected cells and in vivo in mice [17]. The efficacy
of fosfomycin against intracellular L. monocytogenes was independently confirmed by others
[18]. The basis of this in vitro-in vivo paradox is the PrfA-regulated expression of the listerial
sugar phosphate permease Hpt, a homolog of the enterobacterial hexose phosphate transporter
UhpT that also transports fosfomycin [17]. Hpt is a virulence factor that promotes rapid repli-
cation in the cytosol by allowing bacterial utilization of host-cell hexose phosphates as a carbon
source [19]. However, Hpt remains unexpressed outside the host due to PrfA On-Off switch-
ing [17, 20], preventing Hpt-mediated fosfomycin import into the listerial cell [17]. Impor-
tantly, we also showed that L. monocytogenes spontaneous fosfomycin resistance was mostly
due to mutations in the prfA (56%) or hpt (41%) genes [17]. Since prfA is essential for patho-
genesis [6, 21] and hpt is required for full in vivo virulence [19], L. monocytogenes fosfomycin
resistant mutants were consequently found to be counterselected in infected macrophages
[17].
Virulence-resistance gene epistasis in Listeria
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Despite the above evidence, a potential obstacle for the clinical use of fosfomycin in the
treatment of listeriosis is the reported presence in L. monocytogenes of a fosfomycin hydrolyz-
ing enzyme, FosX [22]. The fosX gene was originally discovered in the soil bacteria Mesorhizo-
bium loti and Desulfitobacterium hafniense and in the L. monocytogenes reference genome
strain EGDe (lmo1702) by in silico mining for homologs of the fosfomycin resistance proteins
FosA and FosB [23]. However, the actual distribution of fosX, and whether this gene actually
confers fosfomycin resistance in L. monocytogenes had not been established.
In this study, we show that fosX is a core trait of the Listeria genus that confers high levels of
resistance to fosfomycin unless epistatically controlled, in the pathogenic species L. monocyto-
genes, by members of the in vivo-activated PrfA virulence regulon. Our work demonstrates
that epistatic interactions between virulence and resistance genes can have dramatic effects on
the antimicrobial susceptibility phenotype of bacterial pathogens.
Results
fosX is part of the Listeria core genome
Analysis of a collection of genomic sequences from 1,696 L. monocytogenes isolates from 13
countries, representing the four lineages of the species, 164 sublineages and 1,013 core-genome
MLST subtypes [24], showed that the fosX gene is universally conserved in L. monocytogenes
(Fig 1A). L. monocytogenes strains encoded a 133-residue FosX protein between 92 and 100%
identical to the product of the 402-bp fosX gene of strain EGDe [23] (S1 Table). No other puta-
tive fosfomycin resistance enzyme genes were identified in L. monocytogenes. FosX orthologs
were also encoded in Listeria innocua, Listeria welshimeri (89% identity), Listeria marthii (91%
identity) and Listeria ivanovii (73% identity) (S1 Table). These species belong together with L.
monocytogenes to one of the main phylogenetic subdivisions of the genus, clade (i) or Listeria
“sensu stricto” [25]. With the exception of Listeria seeligeri, in which the gene appears to have
been lost, fosX was present at the same chromosomal location in all members of the Listeria
sensu stricto clade (Fig 1C). This, and the fact that a phylogenetic tree based on the FosX pro-
tein sequence closely mirrored the genus’ phylogenomic structure (Fig 1B), indicated that fosX
is an ancient Listeria trait that evolved with the core genome of these bacteria.
fosX confers intrinsic resistance to fosfomycin in Listeria
To investigate the role of fosX in the L. monocytogenes fosfomycin phenotype, we constructed
an in-frame deletion mutant in L. monocytogenes P14, a serovar 4b human clinical isolate (S2
Table). The fosX null mutation caused a strong reduction in the fosfomycin minimum inhibi-
tory concentration (MIC) in brain-heart infusion (BHI), from1024 of the parental P14 to
45.3 μg/ml (P< 0.0001) (Fig 2, left panel). Knocking out fosX in the representative non-patho-
genic species L. innocua, which like L. monocytogenes shows intrinsic fosfomycin resistance,
had the same effect (Fig 3). Complementation of P14ΔfosX with a single copy of fosX expressed
from its natural promoter (S1 Fig) restored wild-type MIC levels (Fig 2, left panel), demon-
strating that FosX confers strong resistance to fosfomycin on Listeria.
The distribution and high degree of conservation of fosX among pathogenic and obligate
saprotrophic Listeria spp. could be linked to the resistance phenotype, or might be related to
other potential roles of the FosX enzyme in listerial physiology, as suggested for the compo-
nents of the bacterial intrinsic resistomes [26–28]. For example, FosX from the soil bacterium
M. loti is catalytically promiscuous, has a comparatively low capacity to hydrolyze fosfomycin,
and is probably primarily involved in rhizobial metabolism, as indicated by the presence of the
coding gene in a phn operon presumably involved in transport and utilization of phosphonate
[22, 23]. We investigated possible homeostatic roles of Listeria FosX using competition
Virulence-resistance gene epistasis in Listeria
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experiments between wild-type and ΔfosX L. monocytogenes in broth medium and in infected
macrophages in the absence of fosfomycin pressure. FosX was in both cases fitness neutral (Fig
4), indicating that it has no significant housekeeping function, at least in our experimental
conditions.
Interestingly, L. monocytogenes transcription start site mapping data [29] indicate that fosX
(lmo1702) is co-expressed with the upstream gene lmo1703 encoding a putative TrmA super-
family SAM-dependent RNA methyltransferase similar to RlmD/RumA [30] (S1 Fig). This
gene arrangement is unique to Listeria; in fact, fosX genes are found in completely different
genetic environments in each of the bacterial taxa that carry this determinant (S2 Fig). Modifi-
cation of specific rRNA nucleotides by methyltransferases plays a critical role in ribosomal
function regulation and is also a well-known mechanism conferring resistance to ribosomal
antibiotics [31–33]. Specifically, mutagenesis studies of the RmlD/RumA uridine 1939 target
Fig 1. fosX evolved with the Listeria core genome. (A) Single linkage clustering of 1,696 L. monocytogenes isolates based on core-genome MLST
profiles [24] showing the conservation of foxX in the species. Main L. monocytogenes lineages I to IV [24] are indicated in different colors. The
presence of complete fosX coding regions is marked in gray in the outer ring (where gaps indicate strains with frameshift mutations leading to a
truncated FosX protein; see text). (B) Neighbor-joining tree of FosX enzymes from Listeria spp. rooted with Brucella melitensis FosX (NCBI RefSeq
WP_004687281.1). The topology of the tree mirrors the Listeria genus whole-genome phylogeny (which currently includes a number of Listeria-like
groups) [25] and L. monocytogenes diversification into lineages (color coded as in panel A). The Listeria sensu stricto clade is indicated with thick
lines. More distant fosX homologs (possibly paralogs) are present in the Listeria sensu lato “Paenilisteria” clade (represented by L. cornellensis, L.
rocourtiae, L. weihenstephanensis and L. riparia in the tree; 63–65% amino acid sequence identity to L. monocytogenes FosX vs 73–91% for Listeria
sensu stricto orthologs) in a different chromosomal location. See S1 Table for details. (C) Genomic organization around the fosX gene (lmo1702) in
the Listeria sensu stricto clade [25]. Orthologs are in the same color, non-core genes are in gray. fosX is present in all members of the clade except L.
seeligeri. L.m., L. monocytogenes. Coding sequence numbers according to L. monocytogenes EGDe nomenclature.
https://doi.org/10.1371/journal.pgen.1007525.g001
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in the Escherichia coli 23S ribosomal subunit demonstrated altered susceptibility patterns to
antibiotics that affect protein synthesis [34]. Fosfomycin is produced by several species of the
ubiquitous environmental microbes Streptomyces and Pseudomonas [11, 14], which Listeria
spp. are likely to encounter in the natural habitat. It is tempting to speculate that fosX and the
conserved adjacent rmlD/rumA-like homolog found in Listeria spp. form a “chromosomal
resistance” island conferring simultaneous protection against microbially derived fosfomycin
and ribosome-targeting secondary metabolites. It cannot be excluded, however, that the enzy-
matic activity of FosX may play a more general role in bacterial physiology by mediating epox-
ide ring hydrolysis (23) in some catabolic processes relevant to Listeria.
Evidence for OPA permease-independent fosfomycin import
The fosfomycin susceptibility of P14ΔfosX in BHI raises the question of how fosfomycin might
enter the listerial cell at inhibitory concentrations in conditions where PrfA is “Off” and Hpt is
completely downregulated [17]. A double ΔfosXΔhpt mutant had the same MIC as the fosX
mutant (P = 0.399) (Fig 2, left panel), excluding leaky expression of the Hpt transporter as the
cause. Although a very small molecule (138 Da), fosfomycin is hydrophilic and unlikely to per-
meate into the bacterial cell unless through facilitated diffusion via a carrier protein(s). The
only known bacterial fosfomycin transporters are two types of organophosphate:inorganic
Fig 2. Genetic analysis of the role of fosX, prfA and hpt in L. monocytogenes fosfomycin phenotype. MIC, minimal
inhibitory concentration. Mean ± SD from at least three independent experiments. Relevant P values are indicated
(one-way ANOVA with uncorrected Fisher’s post-hoc multiple comparisons). Left panel: wild-type prfA allele (WT) in
BHI medium (virulence-resting conditions i.e. PrfA system “Off”, Hpt not expressed). Middle panel: WT in charcoal-
supplemented BHI (BHI-Ads; virulence-activating conditions i.e. PrfA system “On”, Hpt expressed). Right panel:
constitutively activated prfA allele in BHI (in vivo-like virulence-activating conditions i.e. PrfA locked “On”, Hpt
expressed). See S2 Table for bacterial constructs. Note: (i) in in vitro (outside host) conditions (left panel), deletion of
fosX renders L. monocytogenes susceptible to fosfomycin (drop in MIC from1,024 to 45.3 μg/ml; susceptibility
breakpoint = 64 μg/ml [18]); (ii) in infection-like conditions (middle and right panels), the activation of the PrfA
system and ensuing increased influx of fosfomycin via the PrfA-regulated organophosphate transporter Hpt overrides
fosX-mediated resistance and L. monocytogenes becomes susceptible to fosfomycin (MICs between 12.0 and 27.3 μg/
ml).
https://doi.org/10.1371/journal.pgen.1007525.g002
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phosphate antiporters (OPA) [35], exemplified by the hexose phosphate transporter UhpT
(and listerial homologue Hpt) and the GlpT glycerol-3-phosphate permease [11, 36]. Genome
searches confirmed that Hpt is the only OPA permease in Listeria spp. This indicates that the
susceptibility of the L. monocytogenes ΔfosXΔhpt mutant (and the L. innocua fosX mutant)
must depend on another, as yet unknown fosfomycin uptake pathway (Fig 5). We suggest that
the selective pressure imposed by this uncharacterized transport mechanism is a major driver
underlying fosX acquisition and maintenance in Listeria.
Fig 3. fosX confers intrinsic fosfomycin resistance to non-pathogenic Listeria.L. innocua strain CLIP 11262 was
used as representative obligate saprotrophic Listeria sp. Data for wild type, fosX knock-out mutant by pLSV1 plasmid
insertion, and revertant thereof in BHI. Identical results were obtained in BHI-Ads. Mean ± SD from three
experiments. Relevant P values are indicated (One-way ANOVA with Dunnett’s multiple comparisons).
https://doi.org/10.1371/journal.pgen.1007525.g003
Fig 4. fosX is fitness neutral. (A) Growth curves of L. monocytogenes P14 (WT) and isogenic ΔfosX mutant in BHI.
Mean ± SEM of five duplicate experiments. (B) Competition experiments between P14 and ΔfosX in BHI (left panel)
and RAW 264.7 mouse macrophages (right panel). BHI broth or RAW 264.7 cell monolayers were inoculated with a
1:1 mix of both bacteria and the competition indexes (C.I.) determined after incubation of 18 h at 37 ˚C or at the
indicated intracellular infection time points. t = 0 corresponds to 1 h after infection (30 min incubation after addition
of inoculum and centrifugation plus 30 min gentamicin treatment). Mean ± SEM of three duplicate experiments, a C.I.
= 1 indicates equal competing ability. One-sample Student´s t test (hypothetical value 1, two tails) P values:
BHI = 0.977; macrophages = 0.2254, 0.874 and0.999 for t = 0, 4 and 8 h, respectively. Similar results as in BHI were
obtained using less rich media (Luria-Bertani broth, C.I. = 0.92± 0.05, P = 0.331; chemically-defined IMM medium, C.
I. = 1.037±0.071, P = 0.657).
https://doi.org/10.1371/journal.pgen.1007525.g004
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Epistasis of the virulence genes prfA and hpt over fosX
We tested the effect of fosX when Hpt-mediated fosfomycin transport is active using two
“infection-mimicking” in vitro conditions: (i) supplementation of BHI medium with an adsor-
bent (activated charcoal or Amberlite XAD-4), which causes the partial activation of the PrfA
regulation system by an as yet not fully understood mechanism [37]; and (ii) use of a constitu-
tively activated prfA allele, where a single amino acid substitution (e.g. PrfAG145S) locks PrfA
in “On” state, causing constitutive activation of the PrfA-regulated virulence genes [38]. A
strong reduction in the fosfomycin MIC is typically observed with each of these two PrfA-acti-
vating strategies [17] (from1024 to 27.3±5.3 and 12±0 μg/ml, respectively; P< 0.0001) (Fig
2, middle and right panels). In these conditions, the fosX mutation lowered further the fosfo-
mycin MIC to virtually complete susceptibility (2.2±0.4 and 1.5±0.4 μg/ml, respectively)
(P = 0.01). Complementation of the ΔfosX mutant restored the MIC to parental levels (Fig 2,
middle and right panels). As expected [17], deletion of hpt or its transcriptional activator gene
prfA rendered L. monocytogenes resistant to fosfomycin (MIC >1,024 μg/ml) (Fig 2, middle
and right panels) but had no effect on bacteria with a wild-type prfA allele in BHI (where
PrfA is “Off” and hpt is not expressed) (Fig 2, left panel). Ablation of Hpt function in the
Fig 5. Model of virulence-resistance gene epistatic interaction determining L. monocytogenes fosfomycin
phenotype. In saprophytic (in vitro) conditions (left section of figure), the FosX enzyme inactivates the (relatively low)
concentrations of fosfomycin that enter the bacterial cell via an uncharacterized transport mechanism (indicated with
an inward arrow; see text for details). This fosfomycin uptake mechanism operates in both obligate saprotrophic and
pathogenic Listeria spp. However, in L. monocytogenes, two of its virulence determinants, prfA encoding the central
virulence regulator PrfA [4], and the PrfA-regulated hpt gene encoding the sugar phosphate permease Hpt [19] (which
also transports fosfomycin) [17], suppress the effect of FosX. This occurs during infection, where PrfA is activated
upon sensing of host signals [5, 6, 41] and PrfA-promoted expression of Hpt leads to increased fosfomycin influx. In
these conditions, FosX is overwhelmed and a fraction of incoming fosfomycin reaches its MurA target at inhibitory
concentrations (right section of figure). Fosfomycin is shown in molecular structure representation. MurA catalyzes
the first committed step in peptidoglycan biosynthesis (ligation of phosphoenolpyruvate to the 3’-hydroxy group of
UDP-N-acetylglucosamine) [11, 36].
https://doi.org/10.1371/journal.pgen.1007525.g005
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FosX−background under conditions of PrfA activation raised the MIC, from 2.2±0.4 to 36.8
±7.0 μg/ml (charcoal-supplemented BHI [BHI-Ads]) or 1.5±0.4 to 35.2±6.4 μg/ml (prfA allele)
(P<0.001). These higher MIC values were similar to those for ΔfosX (or the double mutant
ΔfosXΔhpt) in BHI (45.3±2.7 μg ml/ml and 41.6±3.9, respectively) (Fig 2).
Overall, the above findings are consistent with a scenario where FosX: (i) can successfully
inactivate the amounts of fosfomycin that enter the bacterial cell via the uncharacterized “con-
stitutive” transport system, conferring complete resistance in in vitro (saprophytic) conditions;
but (ii) is unable to process an increased influx of fosfomycin molecules via the Hpt trans-
porter in PrfA-activating (infection) conditions (Fig 5). In other words, our data show that the
intrinsic resistance conferred by the fosX gene is masked, or epistatically supressed, by the
joint effect of the virulence genes prfA and hpt on fosfomycin transport.
Epistatic effect during infection
We next assessed the extent to which the epistatic effect that cancels fosX-mediated resistance
manifests during infection, where prfA/hpt are naturally induced [5, 6, 39–41]. To this end, the
intracellular susceptibilities of wild-type L. monocytogenes P14 and isogenic ΔfosX derivative
(and Δhpt mutant as a control) were compared in survival/proliferation assays in infected RAW
264.7 macrophages in the presence and absence of fosfomycin. Cell cultures were incubated
with 5× the physiological concentration of D-glucose as in these conditions listerial intracellular
growth is independent of Hpt-mediated hexose phosphate uptake [17]. As shown in Fig 6, both
wild-type and ΔfosX L. monocytogenes were equally susceptible to fosfomycin during intracellu-
lar infection (P = 0.996). In contrast, fosfomycin had in these conditions no effect on the Δhpt
mutant with disabled Hpt transport. Identical results were obtained using the human epithelial
cell line HeLa (Fig 6). These data confirmed that L. monocytogenes is fully susceptible to fosfo-
mycin in infection conditions, specifically as a consequence of the epistatic supression of fosX-
mediated resistance by the PrfA-regulated (in vivo-activated) hpt gene.
PrfA activation does not affect fosX expression
While our data are consistent with the loss of fosX-mediated intrinsic resistance under PrfA
induction (infection) conditions being primarily due to increased fosfomycin influx via Hpt
Fig 6. Fosfomycin susceptibility in infected cells. Intracellular survival of wild-type P14 (WT) and isogenic ΔfosX
mutant demonstrating the lack of effect of FosX on L. monocytogenes susceptibility during infection. Experiments were
conducted in RAW 264.7 macrophages and HeLa epithelial cells incubated with and without 180 μg/ml fosfomycin. A
Δhpt mutant where PrfA-dependent fosfomycin uptake is disabled was included as a control. Mean ± SEM of at least
three duplicate experiments. Relevant P values are indicated; ns, not significant (one-way ANOVA and Sˇı´da´k tests of
data at final time-point).
https://doi.org/10.1371/journal.pgen.1007525.g006
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(Fig 5), potential effects of PrfA (or the intracellular milieu) on fosX expression could also be a
contributing factor. To explore this possibility, fosX transcription was analysed by RT-QPCR
in BHI and in PrfA-activating conditions in vitro (adsorbent-treated medium, prfA allele; see
above) or during intracellular infection. All three PrfA-inducing conditions caused the
expected transcriptional activation of the PrfA-regulated hpt and (control) actA genes [5, 42],
with no significant changes in fosX expression (P = 0.615) (Fig 7). These data excluded a poten-
tial involvement of reduced expression of fosX in the susceptibility phenotype elicited by PrfA
activation.
Fosfomycin susceptibility of L. monocytogenes isolates under PrfA
activation
To establish whether the limited effect of fosX when the PrfA system is “On” and Hpt is
expressed is a general feature of the L. monocytogenes species, the fosfomycin MIC of 142 wild-
type isolates was tested in BHI and BHI-Ads. The MIC50 and MIC90 values shifted from
1,024 μg/ml in BHI to 16 and 64 μg/ml, respectively, in BHI-Ads (Fig 8A). Thus, despite
fosX, in conditions of PrfA activation the fosfomycin MIC remained within the limits of sus-
ceptibility for the vast majority of the tested strains (90.33% with 64 μg/ml PK/PD breakpoint
[18]; 80.64% with 32 μg/ml general fosfomycin breakpoint for gram-positive bacteria [43]). It
must be noted that adsorbents only partially activate PrfA ([41] and Fig 7), and significantly
lower fosfomycin MICs (median 3 μg/ml, range 2–16) are observed in L. monocytogenes
prfAG145S bacteria with the PrfA system constitutively activated to in vivo (within-host)-like
levels [17, 41] (see Fig 2, right panel).
To determine if the above findings can be extrapolated to infection conditions, the intracel-
lular susceptibility of a selection of L. monocytogenes strains with “normal” (i.e. adsorbent-acti-
vable) fosfomycin phenotype was analysed in RAW 264.7 macrophages. The tested bacteria
included eight wild-type human clinical isolates plus the well-characterized strains EGDe (ser-
ovar 1/2a), 10403 (serovar 1/2a) and CLIP 80459 (serovar 4b). In addition, we also tested a
representation (n = 10) of the small proportion of isolates where the fosfomycin MICs re-
mained relatively elevated (96–384 μg/ml) despite being BHI-Ads responsive, to determine if
Fig 7. Constitutive expression of fosX. RT-QPCR transcription analysis of fosX and the PrfA-regulated hpt and
(control) actA genes in L. monocytogenes P14 grown in BHI (PrfA “Off”) and under PrfA-inducing conditions
(BHI-Ads, use of prfAG145S allele in BHI, intracellular infection in RAW 264.7 macrophages). BHI-Ads is Amberlite
XAD-4-supplemented BHI. Mean ± SEM of at least three independent experiments in duplicate. Relevant P values are
indicated (one-way ANOVA with uncorrected Fisher’s post-hoc multiple comparison).
https://doi.org/10.1371/journal.pgen.1007525.g007
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this correlated with differences in intracellular susceptibility. Fig 8B shows that all tested
strains were equally susceptible to fosfomycin in infected macrophages (P = 0.632). These data
confirmed that L. monocytogenes isolates are characteristically susceptible to fosfomycin dur-
ing infection, even if the MIC remains above the 64-μg/ml breakpoint as long as they exhibit
the capacity to respond to PrfA-activating conditions (as tested in BHI-Ads medium).
fosX mutations in constitutively susceptible L. monocytogenes isolates
A percentage of L. monocytogenes clinical isolates exhibit constitutively low fosfomycin MICs
under normal in vitro testing conditions [16] (about 2 to 4.5%; data from L. monocytogenes
antibiotic susceptibility surveillance at Institut Pasteur’s National and WHO Collaborating
Reference Centre for Listeria and ref. [18]). We examined nine human isolates carrying a fosX
gene but presenting a fosfomycin MIC64 μg/ml in PrfA-non-inducing conditions (normal
BHI) to determine the underlying mechanism (S3 Table). All displayed a wild-type PrfA phe-
notype (see Materials and Methods), excluding possible spontaneous prfA (hpt-activating)
mutations as the cause for their constitutive in vitro fosfomycin susceptibility [17]. Consistent
with the key role of the FosX enzyme in the intrinsic in vitro resistance of L. monocytogenes to
fosfomycin, eight of the nine strains analyzed carried fosX mutations (S3 Table). The only iso-
late with wild-type FosX gave a “slow-positive” sugar-phosphate acidification test (S3 Table),
pointing to an increased Hpt activity as the cause. However, no differences in hpt gene expres-
sion (S3 Fig) or in the DNA sequence of the hpt region that could explain the Hpt(+) phenotype
(S3 Table) were identified. Seven of the mutants had a premature stop codon at fosX triplet
128, leading to a truncated product where the lack of the six C-terminal residues most likely
destabilizes FosX’s catalytic site [22] (S4 Fig). The other fosX mutant carried a frameshift muta-
tion at position 88 that introduced premature stop codons from position 89. Complementation
analysis in P14ΔfosX confirmed that the fosX128stop and fosX88frameshift mutant alleles did not
encode active FosX enzymes (BHI MICs: 48 and 32 μg/ml, respectively instead of1,024 with
Fig 8. Fosfomycin susceptibility of L. monocytogenes isolates. (A) MICs of a panel of 142 wild-type isolates in BHI (PrfA “Off”, Hpt–) and charcoal-
supplemented BHI (BHI-Ads; PrfA “On”, Hpt+). (B) Intracellular survival of L. monocytogenes isolates in RAW 264.7 macrophages in the presence and absence of
fosfomycin (180 μg/ml). Three distinct sets of bacterial isolates with different fosfomycin phenotype were included: (i) “normal” adsorbent-activable fosfomycin
susceptibility (WT, n = 11, strains listed in S3 Table), (ii) constitutively susceptible fosfomycin phenotype (“low MIC(BHI) variants”, n = 9 including eight
spontaneous fosX mutants, S3 Table), and (iii) isolates showing a relatively elevated MIC (96–384 μg/ml) in BHI-Ads (“high-MIC(Ads) variants”, n = 10). Data for
P14 are those from Fig 6, included for reference. Mean from at least two independent experiments. Relevant P values are indicated (two-way ANOVA with
Dunnett´s multitple comparison tests); ns, not significant.
https://doi.org/10.1371/journal.pgen.1007525.g008
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wild-type fosX). As expected, similar to the P14ΔfosX (Fig 6), all the spontaneous fosX mutants
showed complete susceptibility to fosfomycin in infected host cells (Fig 8B).
Effect of fosX overexpression on fosfomycin susceptibility
We finally examined the impact of the potential occurrence of fosX overexpression mutants on
the L. monocytogenes fosfomycin phenotype. To approximate this, we expressed the fosX gene
in P14ΔfosX under the control of a strong constitutive gram-positive promoter (Pδ [44]). As
shown in Fig 9A, Pδ drove fosX expression to significantly higher levels compared to an equiv-
alent construct with the native Plmo1703 promoter from which fosX is expressed in L. monocyto-
genes [29]. Fosfomycin susceptibility of the two constructs and mock-complemented ΔfosX
(control) was analyzed in vitro in BHI (PrfA”Off”) and BHI-Ads as well as infected RAW 264.7
macrophages (PrfA “On”). The data show that overexpression of fosX neither modified the in
vitro fosfomycin MIC (specifically in BHI-Ads, P = 0.999) (Fig 9B) nor significantly affected
bacterial susceptibility in infection conditions (percent reduction of intracellular population
respect to untreated control between 99.97 and 99.99% for the three strains) (P = 0.115) (Fig
9C). Thus, promoter mutations leading to increased fosX expression are unlikely to result in
adaptive fosfomycin resistance due to the epistatic effect of prfA/hpt taking prevalence even
when fosX is overexpressed. Why fosX overexpression does not result in increased levels of fos-
fomycin resistance may be related to a variety of reasons, including gene post-transcriptional
control or stoichiometric limitations to enzyme activity, and remains to be investigated.
Discussion
Experimental studies showing that antimicrobial resistance may not only carry fitness costs but
also enhance bacterial performance in vivo [45, 46] have prompted a renewed interest in under-
standing the complex relationships between resistance and virulence [47–49]. A direct link is
obvious when the corresponding determinants are carried on the same mobile genetic element
[47, 50, 51]. Other illustrative examples include the efflux pumps that serve a dual role in both
Fig 9. Fosfomycin susceptibility is not affected by fosX overexpression. L. monocytogenes ΔfosX was complemented
with the integrative plasmid pPL2 carrying the fosX gene expressed from its native Plmo1703 promoter (fosX) or the
strong Pδ promoter (PδfosX), or empty vector as a control. (A) RT-QPCR analysis of fosX transcription in BHI grown
bacteria. (B) Fosfomycin MICs determined in BHI and charcoal-supplemented BHI (BHI-Ads). (C) Percent reduction
of intracellular bacteria in RAW 264.7 macrophages in response to fosfomycin (180 μg/ml) relative to untreated
infected cells. Determined at 23 h of infection. Mean ± SEM of at least three independent experiments. Relevant P
values are indicated (one-way and two-way [panel B] ANOVA with Sˇı´da´k multicomparison test); ns, not significant.
https://doi.org/10.1371/journal.pgen.1007525.g009
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resistance and virulence [52, 53], or when there is co-ordinate modulation or crosstalk between
resistance and virulence gene regulatory networks [49, 51, 54, 55]. Most often, however, the
connection is subtler, detected at population level through epidemiological [56–58] or genome-
wide co-evolution studies [59], likely involving gene-gene interactions [47, 56], and little is
known about the precise underlying molecular mechanisms [48]. In this study, we report a
compelling example of gene interaction where the resistance phenotype conferred by a Listeria
core genome trait is modified by virulence genes specifically present in the genomic background
of the pathogenic species L. monocytogenes, strongly affecting the susceptibility to an antibiotic.
Independently, the loci involved, the fosfomycin resistance gene fosX and the virulence
genes hpt and prfA, are bacterial performance enhancers in the specific conditions for which
they presumably evolved in Listeria, i.e. exposure to naturally occurring phosphonic acid
metabolites or the intracellular compartment of an animal host, respectively. However, in the
(man-made) event of L. monocytogenes simultaneously confronting fosfomycin and the host,
the effect of prfA and hpt is dominantly deleterious and overrides the beneficial effect of fosX
(Fig 5). In such circumstances, hpt and its regulatory gene prfA “stand above” and “stop” the
fosfomycin resistance phenotype conferred by fosX in an archetypal example of epistasis [60,
61], to our knowledge the first to be dissected in molecular mechanistic detail between viru-
lence and resistance genes in a bacterial pathogen.
Gene-gene epistatic interactions are thought to play a critical role in modulating the pheno-
typic expression of antibiotic resistance and its impact on microbial fitness, and thereby in the
evolution of resistance [62–67]. Our findings extend this notion to the relationships between
resistance and virulence, two key specific, clinically relevant pathogen traits. In the particular
case described herein, the characterized virulence-resistance gene interplay renders L. monocy-
togenes susceptible to fosfomycin in vivo during infection although carrying the fosX gene,
which otherwise confers high levels of resistance to the antibiotic.
Our data indicate that, due to the epistatic effect of the virulence genes prfA and hpt (which
cannot be reversed by fosX overexpression), or even naturally occurring spontaneous fosX
mutations, the vast majority of L. monocytogenes strains are expected to be fully susceptible to
fosfomycin in clinical conditions. Together with our earlier finding that acquired fosfomycin
resistance is mostly due to mutations in the virulence genes hpt and prfA, and hence counterse-
lected during infection [17], this report provides the rationale underpinning the use of fosfo-
mycin against a nominally intrinsically resistant L. monocytogenes.
The currently recommended treatment for listeriosis consists in a prolonged course of
amoxicillin or ampicillin at high doses, often in combination with gentamicin [1, 2, 9, 68].
However, aminopenicillins cannot be administered in case of allergy to β-lactams, and genta-
micin has a poor intracellular penetration, does not cross the BBB efficiently, and is nephro-
toxic or ototoxic [10, 69, 70]. Due to its bactericidal activity and synergistic action with many
antimicrobials including β-lactams, aminoglycosides, meropenem, linezolid, daptomycin and
vancomycin, the “old” antibiotic fosfomycin [14] is currently resurging as a therapeutic option
for the treatment of critically ill patients with invasive or systemic bacterial infections [12, 13,
71]. Rapid, effective bactericidal action is paramount in neuromeningeal, bacteremic or
materno-fetal listeriosis to limit disease severity, relapses and fatal outcomes [2, 9, 70, 72, 73].
With a well-established safety record, low plasma protein binding, excellent intracellular pene-
tration, and superior entry through the BBB and placental barrier than β-lactams [11–13, 74],
intravenous fosfomycin may prove highly beneficial in the combination therapy of listeriosis.
Beyond its fundamental implications, the mechanistic characterization of the epistatic interac-
tion between resistance and virulence genes reported here has, therefore, a potential direct
application in the treatment of a life-threatening infectious disease.
Virulence-resistance gene epistasis in Listeria
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Materials and methods
Bacteria and culture conditions
The bacterial strains used in this study are listed in S2 and S3 Tables. L. monocytogenes isolates
in Fig 8 are of diverse origins (clinical human and animal, food, environment) and phyloge-
nomic clades, including lineages I, II and III); they were sourced from Institut Pasteur’s Lis-
teria collection or JV-B laboratory’s isolate collection. Listeria were grown in Brain-Heart
Infusion (BHI, Porcine, BD Difco) and Escherichia coli in Luria-Bertani (LB, Sigma) media
(supplemented with 1% agar w/v and/or antibiotics as appropriate) at 37 ˚C unless otherwise
stated. The PrfA regulon was activated in vitro by supplementing BHI with the adsorbents,
activated charcoal (0.5% w/v, Merck) or Amberlite XAD-4 (1% w/v, Sigma), as previously
described [37] (referred to as “BHI-Ads”).
Bioinformatic analyses
The L. monocytogenes genome dataset (n = 1,696 sequences) was scanned for the presence of
fosX (lmo1702) using the BLASTn algorithm [75] implemented in BIGSdb v.1.16 platform [76]
as described in ref. [24], with minimum nucleotide identity of 70%, alignment length coverage
of 70% and word size of 10. General homology searches were carried out using BLASTP with
default parameters.
fosX constructs
L. monocytogenes P14 fosX deletions were made by allelic exchange using the thermosensitive
shuttle vector pMAD [77] as previously described [7]. A DNA fragment containing an in-
frame ΔfosX allele comprising the last five 5’- and 3’-terminal codons of the wild-type gene was
prepared by splicing overlap extension PCR using oligonucleotides fosXDM-1 NcoI and
fosXDM-4 BamHI (S4 Table), as previously described [5]. The PCR product was inserted into
pMAD using the NcoI and BamHI restriction sites and the resulting pMADΔfosX plasmid (S2
Table) was transformed into L. monocytogenes. Allelic exchange was selected at the vector-
non-permissive temperature of 42 ˚C as described in [19] and verified by PCR and DNA
sequencing. For complementation, a single copy of the fosX gene from P14 was inserted into
the L. monocytogenes chromosome under the control of its native Plmo1703 promoter [29] (S1
Fig) using the integrative vector pPL2 [78] (S2 Table). The Plmo1703:fosXP14 fusion was con-
structed by ligating two PCR products, one containing the 5’ UTR region of lmo1703 including
the promoter, the other the coding sequence of fosX from strain P14, using the NdeI site
included in the 5’ tails of oligonucleotides Plmo1703-NdeI-R and fosX-ATG-NdeI-F (S4
Table). The resulting ligation product was inserted in the multicloning site (MCS) of pPL2
using SacI-SalI sites (plasmid pPLPlmo1703:fosXP14, S2 Table). For fosX overexpression, the fosX
gene plus 45 bp upstream was placed under the control of the strong constitutive Pδ promoter
from the streptococcal pSM19035 plasmid partitioning gene δ [44] and inserted into pPL2’s
MCS using SpeI-BamHI sites (plasmid pPLPδ:fosXP14, S2 Table). pPL2 integrants were selected
in BHI containing 7.5 μg/ml chloramphenicol and confirmed by PCR and DNA sequencing.
The L. innocua fosX gene was knocked out by plasmid insertional mutagenesis. A 363-bp inter-
nal fosX gene fragment was PCR-amplified (see oligonucleotides in S4 Table) and ligated into
the BamHI-EcoRI sites of the thermosensitive vector pLSV1 [79]. The resultant pLSV-fosXLi
plasmid was introduced into L. innocua CLIP11262 (S2 Table) and the recombinant clones
were selected at 42 ˚C in BHI containing 5 μg/ml erythromycin. L. innocua wild-type fosX
revertants were obtained by serial passage in BHI without erythromycin and selected on
150 μg/ml fosfomycin, a concentration that is inhibitory when the fosX gene is inactivated (see
Virulence-resistance gene epistasis in Listeria
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Fig 2). Correct plasmid insertion and subsequent plasmid loss and restoration of the wild-type
fosX allele was confirmed by PCR and DNA sequencing. Restriction enzymes were obtained
from New England Biolab and high-fidelity PfuUltra II Hotsart DNA polymerase from
Agilent.
Fosfomycin susceptibility testing
Fosfomycin MICs were determined by the Etest strip method (bioMe´rieux) after 24 h incuba-
tion at 37 ˚C as previously described [17].
Characterization of PrfA phenotype
The functional status of PrfA was determined using the activities of three PrfA-regulated viru-
lence determinants used as reporters (hly encoding the hemolysin listeriolysin O [LLO], plcB
encoding the phosphatidyl-choline preferring phospholipase C/lecithinase PlcB, and hpt
encoding the Hpt sugar phosphate permease), as previously described [7, 17, 37]. Briefly,
LLO activity was determined by the halo of hemolysis around Listeria colonies in sheep blood
agar (SBA, bioMe´rieux); PlcB activity was determined by the halo of precipitation in BHI sup-
plemented with 10% of an egg yolk suspension, prepared by dispersing one egg yolk in 100 ml
of sterile saline solution; and Hpt activity was determined using a sugar acidification test in
phenol red base broth (Oxoid) supplemented with 10 mM glucose-1-phosphate after 24 h
incubation (G1P, Sigma). PlcB and Hpt tests were carried out also with and without supple-
mentation with 0.5% activated charcoal. Using this panel of tests, the L. monocytogenes wild-
type phenotype is characterized by: (i) weak hemolysis in SBA (confined to the area beneath
the colonies), (ii) negative lecithinase reaction and G1P utilization in non-charcoal-supple-
mented media; and (iii) strong lecithinase and G1P acidification in charcoal-supplemented
medium. A PrfA phenotype is characterized by (i) strong hemolysis in SBA and (ii) strong
lecithinase and positive G1P in non-charcoal-supplemented medium.
Competition assays
Inocula for the competition assays were prepared from L. monocytogenes overnight BHI cul-
tures shaken at 200 rpm until OD6001. Bacteria were collected by centrifugation, washed
twice in PBS, suspended in 10% glycerol PBS and stored at -80˚C in 100μl aliquots. Viable
numbers of each P14 and P14ΔfosX strains in the frozen alliquots were determined by plate
counting and suitable amounts mixed to prepare a 1:1 suspension. For the in vitro competition
assays in BHI, five ml of fresh culture medium were seeded with 40 μl of the 1:1 suspension of
P14 and P14ΔfosX (2×106 CFU/ml total bacteria) and growth was monitored during incuba-
tion with orbital shaking (200 rpm) using an automated plate reader (Omega apparatus, BMG
Labtech), as previously described [7]. For assays in infected cells, mycoplasma-free RAW 264.7
mouse macrophage monolayers (sourced from ATCC) grown in Dulbecco modified Eagle
medium supplemented with 10% fetal bovine serum (Gibco) (DMEM) were inoculated with
the 1:1 bacterial suspension at a multiplicity of infection of 10 and intracellular bacterial prolif-
eration monitored using a gentamicin protection assay, as previously described [5]. The com-
peting wild-type and ΔfosX bacteria were enumerated by differential plating in BHI and BHI
supplemented with 100 μg/ml fosfomycin (inhibitory for L. monocytogenes ΔfosX, MIC
45.3 μg/ml; Fig 2). The genotype of the bacterial strains was further confirmed by PCR in 50
randomly selected colonies using oligonucleotides fosXDM-5 and fosXDM-6 (S4 Table). The
competitive index (CI) was calculated using the formula CI = (test/reference log CFU ratio at
t = n)/(test/reference log CFU ratio at t = 0).
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Intracellular susceptibility assays
The effect of fosfomycin on intracellular L. monocytogenes was determined as previously
described [17]. Briefly, 80–90% confluent monolayers of RAW 264.7 macrophages or HeLa
epithelial cells (ATCC) were infected at 10:1 or 25:1 multiplicity, respectively, and centrifuged
at 900 rpm to synchronize infection. After 30 min of incubation, infected monolayers were
washed with PBS to remove extracellular bacteria and incubated in DMEM containing 100 μg/
ml gentamicin for 30 min (t = 0). At 40 min after t = 0, the medium was changed to 25 μg/ml
gentamicin with or without 180 μg/ml fosfomycin.
Gene expression analysis
Total L. monocytogenes RNA was extracted from mid-exponential cultures (OD600 0.2–0.3
for BHI media) or intracellular bacteria (t = 4 h) using RNease mini kit (Qiagen). RNA samples
were reverse transcribed using ImProm-IITM reverse transcription system (Promega) and spe-
cific cDNAs quantified by real-time PCR (RT-QPCR) as previously described [5] using Step
One Plus real-time PCR apparatus and Step One V2.3 software (Applied Biosystems). The
PCR signal was monitored using TaqMan probes for the PrfA-regulated genes hpt and actA,
and Power SYBR Green master mix (Applied Biosystems) and gene-specific primers for fosX.
Transcription values of the target genes were normalized using the housekeeping genes rpoB
and ldh. Fold-changes in fosX expression were determined by the 2–ΔΔCT method. The oligo-
nucleotides used are shown in S4 Table.
Statistical analysis
Statistical significance was analyzed using Prism 7.0 software (GraphPad Software Inc., San
Diego, CA). The specific tests used are indicated in the figure legends.
Accession codes
Sequence data obtained in this study are available from the European Nucleotide Archive
(ENA) under accession no. LT795753, LT795754, LT795755, LT795756, LT795757, LT795758,
LT795759, LT795760, LT795761, LT795762.
Supporting information
S1 Fig. Genetic and transcriptional organization of L. monocytogenes fosX locus. Based on
detailed transcription unit mapping of the L. monocytogenes EGDe genome by massive strand-
specific cDNA sequencing [29]. Transcription start site and terminator are indicated. Color
codes of genes as in Fig 1C.
(TIF)
S2 Fig. Genetic structure of fosX locus in different bacteria. Schematic representation com-
paring the genomic regions around the fosX gene (in black) in a selection of bacteria from
different phyla showing highest FosX amino acid sequence similarity to Listeria. Putative func-
tions encoded are indicated; HP, hypothetical protein. Note that the fosX region in each bacte-
rial species has a different genetic structure (color codes of Listeria genes as in Fig 1C, non-
matching genes in other species are shown in grey). Genome sequences analyzed (NCBI acces-
sion nos.): Pelosinus fermentans A11 (NZ_AKVM01000112.1), Brevibacillus thermoruber PM1
(NZ_JQMH01000006.1), Enterococcus silesiacus DSM 22801 (NZ_JXLC01000010.1), Bacillus
patagoniensis DSM 16117 (NZ_KV917377.1), Clostridium botulinum F634 (CP013707.1), M.
loti NZP2014 (LYTJ01000024.1), D. hafniense TCP-A (NZ_KB900391.1), Sulfitobacter
Virulence-resistance gene epistasis in Listeria
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1007525 September 4, 2018 15 / 21
mediterraneus DSM 12244 (NZ_QBKU01000002.1), Brucella melitensis S66
(NZ_AHWB01000021.1), Synechococcus sp. PCC 6312 (NC_019680.1). Genes not at exact
scale.
(TIF)
S3 Fig. Expression of hpt gene in L. monocytogenes fosX mutants with “slow-positive” Hpt
phenotype. Transcription analysis of hpt gene and control PrfA-regulated actA gene deter-
mined by RT-QPCR in PAM 3393 and PAM 3415 mutants (see S3 Table) and wild-type L.
monocytogenes P14 grown in BHI (PrfA “Off”). Mean ± SEM of four independent experiments
in duplicate. One-way ANOVA with Dunnett´s multitple comparison tests; ns, not significant.
(TIF)
S4 Fig. Structural analysis of spontaneous fosX128stop mutation. A premature stop codon at
triplet 128 (of 133) of the L. monocytogenes fosX gene was present in seven out of nine constitu-
tively susceptible L. monocytogenes human clinical isolates tested (see text). Complementation
analysis showed that the fosX128stop allele is non-functional, indicating that the truncated FosX
product is either inactive or unstable. The three-dimensional structure of the L. monocytogenes
FosX metalloenzyme dimer [22] (PDB 2P27; from serovar 4b strain ATCC19115, with FosX of
P14 sequence type, see S3 Table) is shown with polypeptide chains in green and gray. The C-
terminal region missing in the truncated FoxX polypeptide (residues 128–133, in blue) appears
to play a critical role in stabilizing the cup-shaped metal coordination/catalytic site of the
enzyme [22] via hydrophobic interactions with residues from the three-stranded antiparallel
β-sheet domain in the opposite protomer (Leu128 with Ile31’, Tyr32’, Phe46’ and, indirectly
via Leu124, Trp53’; Tyr131 with Tyr32’; in sphere representation except Ile31’). Mn(II) ions
are in magenta, the bound sulfate ion expected to indicate the position of the phosphonate
group of fosfomycin is in stick representation with colored atoms.
(TIF)
S1 Table. Distribution of fosX in Listeria spp. FosX orthologs (73–91% identity, 100% cover-
age over 133 residues) are encoded in all Listeria sensu stricto species except L. seeligeri. FosX
paralogs (63–66% amino acid sequence identity, i.e. similar to the level of homology with FosX
proteins from more distantly related bacteria) are encoded in a different chromosomal loca-
tion in the Listeria sensu lato “Paenilisteria” clade except L. grandensis (in L. cornellensis and L.
rocourtiae the gene is truncated). More distant paralogs are encoded in Murraya grayi (55%
identity, truncated) and Listeria sensu lato “Mesolisteria” clade. (23–55%). FosX homologs
from other Firmicutes and α-Proteobacteria bacteria originally described in ref. [23] are
included for reference.
(PDF)
S2 Table. Strains and plasmids. Used in the genetic analysis of the role of fosX, hpt and prfA
in Listeria fosfomycin susceptibility.
(PDF)
S3 Table. Analysis of PrfA phenotype and fosX genotype of L. monocytogenes clinical iso-
lates constitutively susceptible to fosfomycin (BHI MIC64 μg/ml). Human isolates with
wild-type fosfomycin susceptibility pattern (resistant in BHI and susceptible in BHI-Ads),
including a selection of strains showing lowest MICs in the resistance range in BHI, were also
sequenced as controls. Reference strains: P14, P14 prfA and EGDe. Two other well-character-
ized L. monocytogenes strains (10403S and CLIP 80459) were also analyzed.
(PDF)
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S4 Table. Main oligonucleotides used in this study. Relevant restriction sites are underlined.
(PDF)
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